Delving into the Latest Updates on LPS-001 with Synapse

Overview

Basic Info

Drug Type

Biosimilar

Synonyms

Target-

Mechanism-

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 2

Inactive Indication-

Originator Organization

Lepu Pharmaceuticals Co., Ltd.

Active Organization

Lepu Pharmaceuticals Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：以乐普药业股份有限公司研发的LPS-001注射液为受试药，以Novo Nordisk A/S生产的司美格鲁肽注射液(诺和泰®)为参照药，比较LPS-001注射液与诺和泰®在中国健康受试者单次给药后的药代动力学特征的相似性。次要目的：比较LPS-001注射液与诺和泰®在中国健康成人受试者中的安全性。

[Translation]

Primary objective: To compare the similarity of the pharmacokinetic characteristics of LPS-001 injection and Novota® after a single dose in healthy Chinese subjects, using LPS-001 injection developed by Lepu Pharmaceutical Co., Ltd. as the test drug and semaglutide injection (Novota®) produced by Novo Nordisk A/S as the reference drug. Secondary objective: To compare the safety of LPS-001 injection and Novota® in healthy Chinese adult subjects.

Start Date20 Jul 2024

Sponsor / Collaborator

Lepu Pharmaceuticals Co., Ltd.

100 Clinical Results associated with LPS-001

Login to view more data

100 Translational Medicine associated with LPS-001

Login to view more data

100 Patents (Medical) associated with LPS-001

Login to view more data

100 Deals associated with LPS-001

Login to view more data